Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug 1;35(8):1279-1281.
doi: 10.1093/ndt/gfaa197.

The clinical characteristics of coronavirus-associated nephropathy

Affiliations
Comment

The clinical characteristics of coronavirus-associated nephropathy

Björn Meijers et al. Nephrol Dial Transplant. .
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Schematic representation of the potential contribution of various renal manifestations of SARS-CoV-2 infection, including COVAN, to an increased risk of mortality. COVAN presents itself as loss of glomerular filtration rate, microscopic haematuria and/or proteinuria. These have all been associated with overall mortality, although a causal relationship has not been proven. In addition, pre-existent CKD is a modifier of the risk of COVID-19-associated mortality.

Comment on

References

    1. Zhu N, Zhang D, Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733 - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720 - PMC - PubMed
    1. Portolés J, Marques M, Lopez P. et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant 2020; 35: 1353–1361 - PMC - PubMed
    1. Yan R, Zhang Y, Li Y. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444–1448 - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280 - PMC - PubMed